Roivant Sciences Ltd., a prominent biotech company operating within the healthcare sector, has recently disclosed insider trading activities involving one of its directors, Melissa Epperly. The company, which specializes in the discovery, development, and commercialization of transformative medicines and technologies across therapeutic areas such as immunology, oncology, hematology, and dermatology, is headquartered in New York, United States. Roivant Sciences is publicly traded on the Nasdaq stock exchange.
On October 5, 2026, Roivant Sciences filed a Form 4 with the Securities and Exchange Commission (SEC), detailing changes in the holdings of Melissa Epperly. The filing revealed several transactions involving the company’s common shares and related stock options. Notably, Epperly acquired 17,750 shares at approximately $4.46 per share. Additionally, she sold 16,850 shares at around $36.08 each and subsequently sold another 900 shares near $36.57 each. These transactions are part of routine insider trading activities conducted under the company’s Rule 10b‑5‑1 trading plan.
Furthermore, the filing recorded a fully vested award of stock options granted to Epperly, allowing her to purchase 17,750 shares at an exercise price of $4.46. These options are set to expire in July 2032. Such disclosures provide transparency regarding the director’s current ownership position in Roivant Sciences Ltd.
As of October 6, 2026, Roivant Sciences’ stock closed at $34.75. The company’s market capitalization stands at approximately $25.66 billion USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $42.50 on September 7, 2026, and a 52-week low of $15.90 on October 9, 2025. The company’s price-to-earnings ratio is currently reported at -72.27, reflecting its financial performance and market valuation.
Roivant Sciences continues to focus on its mission to revolutionize the healthcare industry by providing innovative solutions to pressing medical challenges. For more information about the company’s work and offerings, interested parties can visit their website at www.roivant.com .
